TY - JOUR
T1 - Glycosylation of PAMAM dendrimers significantly improves tumor macrophage targeting and specificity in glioblastoma
AU - Sharma, Rishi
AU - Liaw, Kevin
AU - Sharma, Anjali
AU - Jimenez, Ambar
AU - Chang, Michelle
AU - Salazar, Sebastian
AU - Amlani, Imaan
AU - Kannan, Sujatha
AU - Kannan, Rangaramanujam M.
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/9/10
Y1 - 2021/9/10
N2 - Glioblastoma is among the most aggressive forms of cancers, with a median survival of just 15–20 months for patients despite maximum clinical intervention. The majority of conventional anti-cancer therapies fail due to associated off-site toxicities which can be addressed by developing target-specific drug delivery systems. Advances in nanotechnology have provided targeted systems to overcome drug delivery barriers associated with brain and other types of cancers. Dendrimers have emerged as promising vehicles for targeted drug and gene delivery. Dendrimer-mediated targeting strategies can be further enhanced through the addition of targeting ligands to enable receptor-specific interactions. Here, we explore the sugar moieties as ligands conjugated to hydroxyl-terminated polyamidoamine dendrimers to leverage altered metabolism in cancer and immune targeting. Using a highly facile click chemistry approach, we modified the surface of dendrimers with glucose, mannose, or galactose moieties in a well-defined manner, to target upregulated sugar transporters in the context of glioblastoma. We show that glucose modification significantly enhanced targeting of tumor-associated macrophages (TAMs) and microglia by increasing brain penetration and cellular internalization, while galactose modification shifts targeting away from TAMs towards galectins on glioblastoma tumor cells. Mannose modification did not alter TAMs and microglia targeting of these dendrimers, but did alter their kinetics of accumulation within the GBM tumor. The whole body biodistribution was largely similar between the systems. These results demonstrate that dendrimers are versatile delivery vehicles that can be modified to tailor their targeting for the treatment of glioblastoma and other cancers.
AB - Glioblastoma is among the most aggressive forms of cancers, with a median survival of just 15–20 months for patients despite maximum clinical intervention. The majority of conventional anti-cancer therapies fail due to associated off-site toxicities which can be addressed by developing target-specific drug delivery systems. Advances in nanotechnology have provided targeted systems to overcome drug delivery barriers associated with brain and other types of cancers. Dendrimers have emerged as promising vehicles for targeted drug and gene delivery. Dendrimer-mediated targeting strategies can be further enhanced through the addition of targeting ligands to enable receptor-specific interactions. Here, we explore the sugar moieties as ligands conjugated to hydroxyl-terminated polyamidoamine dendrimers to leverage altered metabolism in cancer and immune targeting. Using a highly facile click chemistry approach, we modified the surface of dendrimers with glucose, mannose, or galactose moieties in a well-defined manner, to target upregulated sugar transporters in the context of glioblastoma. We show that glucose modification significantly enhanced targeting of tumor-associated macrophages (TAMs) and microglia by increasing brain penetration and cellular internalization, while galactose modification shifts targeting away from TAMs towards galectins on glioblastoma tumor cells. Mannose modification did not alter TAMs and microglia targeting of these dendrimers, but did alter their kinetics of accumulation within the GBM tumor. The whole body biodistribution was largely similar between the systems. These results demonstrate that dendrimers are versatile delivery vehicles that can be modified to tailor their targeting for the treatment of glioblastoma and other cancers.
KW - Dendrimer
KW - Glioblastoma
KW - Glycosylation
KW - Tumor-associated macrophages
KW - Tumor-targeting
UR - http://www.scopus.com/inward/record.url?scp=85111058105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111058105&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2021.07.018
DO - 10.1016/j.jconrel.2021.07.018
M3 - Article
C2 - 34274384
AN - SCOPUS:85111058105
SN - 0168-3659
VL - 337
SP - 179
EP - 192
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -